𝔖 Bobbio Scriptorium
✦   LIBER   ✦

597 Differential Her family receptor dimerization and downstream signaling in cancer cell lines

✍ Scribed by H. Salimi-Moosavi; P.-Y. Chan-Hui; S. Pidaparthi; S. Singh

Book ID
118621779
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
144 KB
Volume
2
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Anti-HER-3 MAbs inhibit HER-3-mediated s
Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies
✍ Edward Htun van der Horst; Marta Murgia; Martin Treder; Axel Ullrich πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 French βš– 386 KB

## Abstract Two members of the EGF receptor family, HER2 and HER3, act as key oncogenes in breast cancer cells. A MAb against HER2, trastuzumab, interferes with HER2 signaling and istherapeutically effective in humans. Here, we explored the biologic effects of an antibody against HER3 (α‐HER3^ECD^)

HER-2 receptor expression, localization,
HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors
✍ Elizabeth Half; Russell Broaddus; Kathleen D. Danenberg; Peter V. Danenberg; Gre πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 French βš– 393 KB πŸ‘ 1 views

## Abstract The __HER‐2/neu__ oncogene encodes a 185 kD protein that is phosphorylated upon ligand binding to other HER/erbB members and regulates cell growth and differentiation. Given that HER‐2 receptor blockade can inhibit the growth of colon cancer cell lines and tumor xenografts, we investiga

Epidermal growth factor ligand/receptor
Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer
✍ Marco Volante; Silvia Saviozzi; Ida Rapa; Paolo Ceppi; Susanna Cappia; Raffaele πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 396 KB

## Abstract ## BACKGROUND. In recent years, molecular insights shed light on the role of the epidermal growth factor receptor (EGFR) in nonsmall cell lung cancer (NSCLC), and new therapeutic agents, such as the EGFR tyrosine kinase inhibitors, were tested successfully, with responsiveness to those